Lung Carcinoma — Trials

Lung Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,130
Recruiting: 1,129
Ph III recruiting: 164
Growth YoY: +0.2%
Industry share: 43%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,179)

clinicaltrialsPublishedShowing 151–200 of 450 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07550920	Relatrilfa-α Plus Single-Agent Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III NSCLC (Phase 2)	not yet recruiting	Phase 2	18	Tianjin Medical University Cancer Institute and HospitalOTHER	0	Apr 24, 2026	clinicaltrials
NCT07551414	Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI	not yet recruiting	Phase 2	38	Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER